Bioventus Inc. Class A (BVS) Peer Comparison

$13.87

$0.08 (0.58%)

As on 28-Aug-2026 13:35EDT

Market cap

$982 Mln

Revenue (TTM)

$582 Mln

P/E Ratio

18.4

P/B Ratio

4.3

Div. Yield

0 %

Edit

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	982	12,753	10,906	10,222	9,762
Revenue ($ Mln)	582	1,505	613	785	2,589
Net Profit ($ Mln)	54.46	160.59	-188.05	41.54	222.40
Net Margin (%)	9.36	10.67	-30.68	5.29	8.59
RoE (%)	23.01	10.86	-28.10	1.97	3.04
Price to Earnings	18.44	79.35	--	251.57	44.47
Price-To-Book	4.28	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	581.85	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	186.20	483.98	127.96	384.30	1,245.50
Gross Profit	382.43	942.44	393.22	347.62	1,343.60
Operating Expenses	333.81	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	61.83	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	38.64	203.83	-192.83	52.15	350.40
Provision for Tax	-22.84	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	54.46	160.59	-188.05	41.54	222.40
Minority Interest	-7.01	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	228.31	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	-7.01	0.00	0.00	0.00	0.00
Non-Current Liabilities	243.48	210.18	135.71	705.49	2,116.80
Current Liabilities	152.45	233.78	102.33	132.66	961.30
Total Liabilities	683.56	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	415.82	630.60	404.74	1,749.63	7,231.50
Current Assets	257.53	1,344.12	515.78	1,200.55	3,020.50
Total Assets	683.56	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	263.75	212.71	102.84	690.94	1,203.70
Net Current Assets	105.08	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	73.98	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-3.25	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-61.44	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	4.64	11.76	-22.53	1.79	8.98
ROE (%)	23.01	10.86	-28.10	1.97	3.04
ROA (%)	6.34	7.95	-18.00	1.36	2.02
EBIT Margin (%)	6.73	13.63	-30.58	9.87	-5.99
Net Margin (%)	9.36	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	3.14	17.55	41.55	16.49	1.37
EBIT Growth (%)	9.24	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	34,570.89	8.72	-102.66	400.42	-30.32
EPS Growth (%)	10,561.83	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	36.99	17.33	-12.65	2.16	2.19

Valuation Ratios

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	22.56	68.93	-34.59	189.42	--
Price / Book Value	2.78	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	7.79	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	1.01	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.10	0.01	0.00	0.01	0.06
Current Ratio	1.69	5.75	5.04	9.05	3.14
Quick Ratio	1.17	3.86	4.46	7.64	2.33
Interest Coverage	2.94	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Bioventus Inc. Class A (BVS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	23.79	12.65	22.67	20.09	17.06
Asset Turnover	0.68	0.74	0.59	0.26	0.24
Receivable days	82.20	46.54	60.95	72.41	65.39
Inventory Days	171.86	331.92	193.84	146.53	221.09
Payable days	34.05	26.16	60.19	29.05	37.02
Cash Conversion Cycle	220.00	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly